Asosiy kontentga oʻtish
Maqola

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Mattia D’AgostinoJanssen (Switzerland)David A. CairnsKaryopharm Therapeutics (United States)Juan José LahuertaMundipharma (Inst)Ruth WesterDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the NetherlandsUta BertschJanssen (Switzerland)Anders WaageMundipharma (Germany)Elena ZamagniKaryopharm Therapeutics (United States)María‐Victoria MateosComplejo Asistencial Universitario de Salamanca/IBSAL/CIC/Ciberonc, Salamanca, SpainDaniele Dall’OlioUniversity of BolognaNiels W.C.J. van de DonkVrije Universiteit AmsterdamGraham JacksonUniversity of Newcastle upon Tyne, Newcastle upon Tyne, United KingdomSerena RocchiDipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, ItalyHans SalwenderAsklepios Tumorzentrum Hamburg, AK Altona and AK St Georg, Hamburg, GermanyJoan Bladé CreixentiHospital Clinic, IDIBAPS, Barcelona, SpainBronno van der HoltHOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the NetherlandsGastone CastellaniDipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, ItalyFrancesca BonelloMundipharma (Germany)Andréa CapraJanssen (Switzerland)K. EliasGlaxoSmithKline (France)Jan DürigDepartment of Hematology, University Clinic Essen, Essen, GermanyFrancesca GayJanssen (Switzerland)Sonja ZweegmanVrije Universiteit AmsterdamMichèle CavoIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Bologna, ItalyMartin KaiserThe Institute of Cancer Research, London, United Kingdom and The Royal Marsden Hospital, London, United KingdomHartmut GoldschmidtGlaxoSmithKline (France)Jesús María Hernández‐RivasCentro de Investigación del CáncerAlessandra LaroccaMundipharma (Inst)Gordon CookJanssen (Switzerland)Jesús F. San MiguelClínica Universidad de Navarra, CIMA, IDISNA, CIBER-ONC (CB16/12/00369), Pamplona, SpainMario BoccadoroCelgene, Janssen, Amgen, Karyopharm Therapeutics, CARsgen Therapeutics Research Funding: Janssen (Inst), Amgen (Inst), Skyline DiagnosticsPieter SonneveldDepartment of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands
2022en
ABI

Annotatsiya

PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model. Moreover, chromosome 1q gain/amplification (1q+) recently proved to be a poor prognostic factor. In this study, we revised the R-ISS by analyzing the additive value of each single risk feature, including 1q+. PATIENTS AND METHODS: The European Myeloma Network, within the HARMONY project, collected individual data from 10,843 patients with NDMM enrolled in 16 clinical trials. An additive scoring system on the basis of top features predicting progression-free survival (PFS) and overall survival (OS) was developed and validated. RESULTS: In the training set (N = 7,072), at a median follow-up of 75 months, ISS, del(17p), lactate dehydrogenase, t(4;14), and 1q+ had the highest impact on PFS and OS. These variables were all simultaneously present in 2,226 patients. A value was assigned to each risk feature according to their OS impact (ISS-III 1.5, ISS-II 1, del(17p) 1, high lactate dehydrogenase 1, and 1q+ 0.5 points). Patients were stratified into four risk groups according to the total additive score: low (Second Revision of the International Staging System [R2-ISS]-I, 19.2%, 0 points), low-intermediate (II, 30.8%, 0.5-1 points), intermediate-high (III, 41.2%, 1.5-2.5 points), high (IV, 8.8%, 3-5 points). Median OS was not reached versus 109.2 versus 68.5 versus 37.9 months, and median PFS was 68 versus 45.5 versus 30.2 versus 19.9 months, respectively. The score was validated in an independent validation set (N = 3,771, of whom 1,214 were with complete data to calculate R2-ISS) maintaining its prognostic value. CONCLUSION: The R2-ISS is a simple prognostic staging system allowing a better stratification of patients with intermediate-risk NDMM. The additive nature of this score fosters its future implementation with new prognostic variables.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba